Super Macrophages: New drugs that enhance killing of tuberculosis and other bacteria

Our group has developed the first inhibitors of the nitric oxide-regulating protein family known as SPSB. These inhibitors cause increased NO levels in macrophages and improve macrophage killing of bacteria including M. tuberculosis. We are currently developing a range of inhibitors that include cyclic peptides and small molecules. Lead compounds will be the first members of this exciting new class of antibiotics.

Enhanced research experiences